240 related articles for article (PubMed ID: 8143464)
1. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
[TBL] [Abstract][Full Text] [Related]
2. Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study.
Fisher CJ; Marra MN; Palardy JE; Marchbanks CR; Scott RW; Opal SM
Crit Care Med; 1994 Apr; 22(4):553-8. PubMed ID: 8143463
[TBL] [Abstract][Full Text] [Related]
3. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.
Rogy MA; Moldawer LL; Oldenburg HS; Thompson WA; Montegut WJ; Stackpole SA; Kumar A; Palladino MA; Marra MN; Lowry SF
Ann Surg; 1994 Jul; 220(1):77-85. PubMed ID: 8024362
[TBL] [Abstract][Full Text] [Related]
4. Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides.
Wood DM; Parent JB; Gazzano-Santoro H; Lim E; Pruyne PT; Watkins JM; Spoor ES; Reardan DT; Trown PW; Conlon PJ
Circ Shock; 1992 Sep; 38(1):55-62. PubMed ID: 1394865
[TBL] [Abstract][Full Text] [Related]
5. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
[TBL] [Abstract][Full Text] [Related]
6. Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides.
Parent JB; Gazzano-Santoro H; Wood DM; Lim E; Pruyne PT; Trown PW; Conlon PJ
Circ Shock; 1992 Sep; 38(1):63-73. PubMed ID: 1382882
[TBL] [Abstract][Full Text] [Related]
7. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.
Ooi CE; Weiss J; Doerfler ME; Elsbach P
J Exp Med; 1991 Sep; 174(3):649-55. PubMed ID: 1875165
[TBL] [Abstract][Full Text] [Related]
8. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
9. Reduction of endotoxin-induced vascular permeability by monoclonal antibodies against lipopolysaccharide determinants.
Rubin RM; Noland J; Rosenbaum JT
Circ Shock; 1992 Mar; 36(3):217-23. PubMed ID: 1377103
[TBL] [Abstract][Full Text] [Related]
10. Characterization of two monoclonal antibodies directed against bactericidal/permeability-increasing protein.
Dentener MA; Smit FT; Francot GJ; Buurman WA
J Infect Dis; 1994 Dec; 170(6):1483-9. PubMed ID: 7995988
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of hemorrhage-induced bacteria/endotoxin translocation in rats. Effects of recombinant bactericidal/permeability-increasing protein.
Yao YM; Bahrami S; Leichtfried G; Redl H; Schlag G
Ann Surg; 1995 Apr; 221(4):398-405. PubMed ID: 7726676
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal anti-lipid A IgM antibodies HA-1A and E-5 recognize distinct epitopes on lipopolysaccharide and lipid A.
Fujihara Y; Bogard WC; Lei MG; Daddona PE; Morrison DC
J Infect Dis; 1993 Dec; 168(6):1429-35. PubMed ID: 7504034
[TBL] [Abstract][Full Text] [Related]
13. Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability-increasing protein and its bioactive 23-kilodalton NH2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli.
Capodici C; Chen S; Sidorczyk Z; Elsbach P; Weiss J
Infect Immun; 1994 Jan; 62(1):259-65. PubMed ID: 8262637
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.
Arditi M; Zhou J; Huang SH; Luckett PM; Marra MN; Kim KS
Infect Immun; 1994 Sep; 62(9):3930-6. PubMed ID: 8063410
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation.
Wilde CG; Seilhamer JJ; McGrogan M; Ashton N; Snable JL; Lane JC; Leong SR; Thornton MB; Miller KL; Scott RW
J Biol Chem; 1994 Jul; 269(26):17411-6. PubMed ID: 7517398
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant bactericidal/permeability-increasing protein on endotoxin translocation and lipopolysaccharide-binding protein/CD14 expression in rats after thermal injury.
Fang WH; Yao YM; Shi ZG; Yu Y; Wu Y; Lu LR; Sheng ZY
Crit Care Med; 2001 Jul; 29(7):1452-9. PubMed ID: 11445707
[TBL] [Abstract][Full Text] [Related]
17. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide.
Gazzano-Santoro H; Parent JB; Grinna L; Horwitz A; Parsons T; Theofan G; Elsbach P; Weiss J; Conlon PJ
Infect Immun; 1992 Nov; 60(11):4754-61. PubMed ID: 1398985
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the response to bacterial lipopolysaccharide by endogenous and exogenous lipopolysaccharide binding proteins.
Marra MN; Thornton MB; Snable JL; Leong S; Lane J; Wilde CG; Scott RW
Blood Purif; 1993; 11(2):134-40. PubMed ID: 7506040
[TBL] [Abstract][Full Text] [Related]
19. Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits.
Garcia C; Saladino R; Thompson C; Hammer B; Parsonnet J; Wainwright N; Novitsky T; Fleisher GR; Siber G
Crit Care Med; 1994 Aug; 22(8):1211-8. PubMed ID: 8045139
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand.
Appelmelk BJ; An YQ; Thijs BG; MacLaren DM; de Graaff J
Infect Immun; 1994 Aug; 62(8):3564-7. PubMed ID: 8039930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
